Targeting eEF2K through siRNA or the specific inhibitor NH125 not only impairs key elements of the cholesterol pathway but also suppresses tumor growth by diminishing the levels of SREBP-2 and its downstream targets. Here, SREBF2 is linked to neoplasm.